nodes	percent_of_prediction	percent_of_DWPC	metapath
Ramelteon—CYP1A2—Clobetasol propionate—psoriasis	0.181	0.226	CbGbCtD
Ramelteon—CYP1A2—Methoxsalen—psoriasis	0.0949	0.119	CbGbCtD
Ramelteon—CYP2C19—Cholecalciferol—psoriasis	0.0681	0.0852	CbGbCtD
Ramelteon—CYP3A4—Calcitriol—psoriasis	0.0639	0.08	CbGbCtD
Ramelteon—CYP3A4—Methoxsalen—psoriasis	0.0497	0.0622	CbGbCtD
Ramelteon—CYP2C19—Prednisone—psoriasis	0.0472	0.0591	CbGbCtD
Ramelteon—CYP2C19—Cyclosporine—psoriasis	0.0448	0.056	CbGbCtD
Ramelteon—CYP3A4—Cholecalciferol—psoriasis	0.0329	0.0412	CbGbCtD
Ramelteon—Blood cortisol decreased—Triamcinolone—psoriasis	0.0305	0.189	CcSEcCtD
Ramelteon—CYP2C19—Dexamethasone—psoriasis	0.0295	0.0369	CbGbCtD
Ramelteon—CYP3A4—Mycophenolate mofetil—psoriasis	0.0286	0.0357	CbGbCtD
Ramelteon—CYP3A4—Triamcinolone—psoriasis	0.0286	0.0357	CbGbCtD
Ramelteon—CYP3A4—Betamethasone—psoriasis	0.0245	0.0307	CbGbCtD
Ramelteon—CYP3A4—Prednisolone—psoriasis	0.0242	0.0302	CbGbCtD
Ramelteon—CYP3A4—Hydrocortisone—psoriasis	0.0229	0.0287	CbGbCtD
Ramelteon—CYP3A4—Prednisone—psoriasis	0.0228	0.0286	CbGbCtD
Ramelteon—CYP3A4—Cyclosporine—psoriasis	0.0216	0.0271	CbGbCtD
Ramelteon—CYP3A4—Dexamethasone—psoriasis	0.0143	0.0178	CbGbCtD
Ramelteon—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00254	0.0653	CbGpPWpGaD
Ramelteon—Thinking abnormal—Mycophenolic acid—psoriasis	0.00236	0.0146	CcSEcCtD
Ramelteon—Depression—Methoxsalen—psoriasis	0.00231	0.0143	CcSEcCtD
Ramelteon—Influenza—Fluocinolone Acetonide—psoriasis	0.00205	0.0127	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Fluocinolone Acetonide—psoriasis	0.00191	0.0118	CcSEcCtD
Ramelteon—Anaphylactic shock—Beclomethasone—psoriasis	0.00189	0.0117	CcSEcCtD
Ramelteon—Mental disability—Mycophenolic acid—psoriasis	0.00187	0.0116	CcSEcCtD
Ramelteon—Thinking abnormal—Mycophenolate mofetil—psoriasis	0.00186	0.0115	CcSEcCtD
Ramelteon—Depression—Acitretin—psoriasis	0.00183	0.0113	CcSEcCtD
Ramelteon—Dysgeusia—Methoxsalen—psoriasis	0.00177	0.0109	CcSEcCtD
Ramelteon—MTNR1A—G alpha (i) signalling events—HCAR2—psoriasis	0.00166	0.0428	CbGpPWpGaD
Ramelteon—MTNR1B—G alpha (i) signalling events—HCAR2—psoriasis	0.00166	0.0428	CbGpPWpGaD
Ramelteon—Dysgeusia—Calcitriol—psoriasis	0.00158	0.00975	CcSEcCtD
Ramelteon—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00157	0.0405	CbGpPWpGaD
Ramelteon—Mental disability—Cyclosporine—psoriasis	0.00151	0.00936	CcSEcCtD
Ramelteon—Mental disability—Mycophenolate mofetil—psoriasis	0.00148	0.00913	CcSEcCtD
Ramelteon—Dysgeusia—Acitretin—psoriasis	0.0014	0.00868	CcSEcCtD
Ramelteon—Dysgeusia—Fluocinolone Acetonide—psoriasis	0.0014	0.00865	CcSEcCtD
Ramelteon—Myalgia—Calcitriol—psoriasis	0.00137	0.00848	CcSEcCtD
Ramelteon—Influenza—Mycophenolic acid—psoriasis	0.00135	0.00836	CcSEcCtD
Ramelteon—Insomnia—Methoxsalen—psoriasis	0.00134	0.00825	CcSEcCtD
Ramelteon—MTNR1B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00132	0.034	CbGpPWpGaD
Ramelteon—MTNR1A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00132	0.034	CbGpPWpGaD
Ramelteon—Anaphylactic shock—Calcitriol—psoriasis	0.00132	0.00813	CcSEcCtD
Ramelteon—Anaphylactoid reaction—Cyclosporine—psoriasis	0.00131	0.00809	CcSEcCtD
Ramelteon—Headache—Clobetasol propionate—psoriasis	0.0013	0.00802	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Mycophenolic acid—psoriasis	0.00126	0.00777	CcSEcCtD
Ramelteon—Dizziness—Beclomethasone—psoriasis	0.00125	0.00771	CcSEcCtD
Ramelteon—Dizziness—Fluocinonide—psoriasis	0.00124	0.00764	CcSEcCtD
Ramelteon—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00122	0.0315	CbGpPWpGaD
Ramelteon—Myalgia—Acitretin—psoriasis	0.00122	0.00754	CcSEcCtD
Ramelteon—Arthralgia—Acitretin—psoriasis	0.00122	0.00754	CcSEcCtD
Ramelteon—Arthralgia—Fluocinolone Acetonide—psoriasis	0.00122	0.00752	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Calcitriol—psoriasis	0.0012	0.00741	CcSEcCtD
Ramelteon—Anaphylactoid reaction—Prednisolone—psoriasis	0.00119	0.00736	CcSEcCtD
Ramelteon—Insomnia—Calcitriol—psoriasis	0.00119	0.00735	CcSEcCtD
Ramelteon—Headache—Beclomethasone—psoriasis	0.00118	0.00731	CcSEcCtD
Ramelteon—Headache—Fluocinonide—psoriasis	0.00117	0.00724	CcSEcCtD
Ramelteon—Somnolence—Calcitriol—psoriasis	0.00117	0.00723	CcSEcCtD
Ramelteon—Anaphylactoid reaction—Hydrocortisone—psoriasis	0.00116	0.00719	CcSEcCtD
Ramelteon—Nausea—Beclomethasone—psoriasis	0.00112	0.00693	CcSEcCtD
Ramelteon—Anaphylactoid reaction—Triamcinolone—psoriasis	0.0011	0.00677	CcSEcCtD
Ramelteon—Influenza—Mycophenolate mofetil—psoriasis	0.00107	0.0066	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Acitretin—psoriasis	0.00107	0.00659	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Fluocinolone Acetonide—psoriasis	0.00106	0.00657	CcSEcCtD
Ramelteon—Insomnia—Acitretin—psoriasis	0.00106	0.00654	CcSEcCtD
Ramelteon—Somnolence—Acitretin—psoriasis	0.00104	0.00643	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Cyclosporine—psoriasis	0.00102	0.00629	CcSEcCtD
Ramelteon—Fatigue—Acitretin—psoriasis	0.00101	0.00623	CcSEcCtD
Ramelteon—MTNR1A—GPCR ligand binding—HCAR2—psoriasis	0.00101	0.0259	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR ligand binding—HCAR2—psoriasis	0.00101	0.0259	CbGpPWpGaD
Ramelteon—Anaphylactoid reaction—Betamethasone—psoriasis	0.000994	0.00614	CcSEcCtD
Ramelteon—Anaphylactoid reaction—Dexamethasone—psoriasis	0.000994	0.00614	CcSEcCtD
Ramelteon—Dizziness—Methoxsalen—psoriasis	0.000976	0.00603	CcSEcCtD
Ramelteon—Depression—Cyclosporine—psoriasis	0.000974	0.00601	CcSEcCtD
Ramelteon—Depression—Mycophenolate mofetil—psoriasis	0.00095	0.00587	CcSEcCtD
Ramelteon—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000945	0.0243	CbGpPWpGaD
Ramelteon—Asthenia—Calcitriol—psoriasis	0.000944	0.00583	CcSEcCtD
Ramelteon—Headache—Methoxsalen—psoriasis	0.000925	0.00571	CcSEcCtD
Ramelteon—Influenza—Triamcinolone—psoriasis	0.000916	0.00566	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Hydrocortisone—psoriasis	0.000905	0.00559	CcSEcCtD
Ramelteon—Diarrhoea—Calcitriol—psoriasis	0.0009	0.00556	CcSEcCtD
Ramelteon—Nausea—Methoxsalen—psoriasis	0.000877	0.00542	CcSEcCtD
Ramelteon—MTNR1A—G alpha (i) signalling events—CCL20—psoriasis	0.000863	0.0222	CbGpPWpGaD
Ramelteon—MTNR1B—G alpha (i) signalling events—CCL20—psoriasis	0.000863	0.0222	CbGpPWpGaD
Ramelteon—Upper respiratory tract infection—Triamcinolone—psoriasis	0.000852	0.00526	CcSEcCtD
Ramelteon—Asthenia—Acitretin—psoriasis	0.00084	0.00519	CcSEcCtD
Ramelteon—Headache—Calcitriol—psoriasis	0.000824	0.00509	CcSEcCtD
Ramelteon—Somnolence—Hydroxyurea—psoriasis	0.000817	0.00505	CcSEcCtD
Ramelteon—Myalgia—Mycophenolic acid—psoriasis	0.000803	0.00496	CcSEcCtD
Ramelteon—Arthralgia—Mycophenolic acid—psoriasis	0.000803	0.00496	CcSEcCtD
Ramelteon—Diarrhoea—Acitretin—psoriasis	0.000801	0.00495	CcSEcCtD
Ramelteon—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000799	0.00493	CcSEcCtD
Ramelteon—Fatigue—Hydroxyurea—psoriasis	0.000792	0.00489	CcSEcCtD
Ramelteon—Nausea—Calcitriol—psoriasis	0.000782	0.00483	CcSEcCtD
Ramelteon—Dizziness—Acitretin—psoriasis	0.000774	0.00478	CcSEcCtD
Ramelteon—Dizziness—Fluocinolone Acetonide—psoriasis	0.000772	0.00477	CcSEcCtD
Ramelteon—Dysgeusia—Cyclosporine—psoriasis	0.000747	0.00462	CcSEcCtD
Ramelteon—Headache—Acitretin—psoriasis	0.000733	0.00453	CcSEcCtD
Ramelteon—Headache—Fluocinolone Acetonide—psoriasis	0.000731	0.00452	CcSEcCtD
Ramelteon—Dysgeusia—Mycophenolate mofetil—psoriasis	0.000729	0.0045	CcSEcCtD
Ramelteon—Anaphylactoid reaction—Methotrexate—psoriasis	0.000723	0.00447	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000701	0.00433	CcSEcCtD
Ramelteon—Insomnia—Mycophenolic acid—psoriasis	0.000696	0.0043	CcSEcCtD
Ramelteon—Nausea—Acitretin—psoriasis	0.000695	0.0043	CcSEcCtD
Ramelteon—Nausea—Fluocinolone Acetonide—psoriasis	0.000693	0.00428	CcSEcCtD
Ramelteon—MTNR1A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000686	0.0177	CbGpPWpGaD
Ramelteon—MTNR1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000686	0.0177	CbGpPWpGaD
Ramelteon—Somnolence—Mycophenolic acid—psoriasis	0.000684	0.00423	CcSEcCtD
Ramelteon—Fatigue—Mycophenolic acid—psoriasis	0.000664	0.0041	CcSEcCtD
Ramelteon—Asthenia—Hydroxyurea—psoriasis	0.000659	0.00407	CcSEcCtD
Ramelteon—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000653	0.0168	CbGpPWpGaD
Ramelteon—Arthralgia—Cyclosporine—psoriasis	0.00065	0.00401	CcSEcCtD
Ramelteon—Myalgia—Cyclosporine—psoriasis	0.00065	0.00401	CcSEcCtD
Ramelteon—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000644	0.0166	CbGpPWpGaD
Ramelteon—Depression—Prednisone—psoriasis	0.000644	0.00398	CcSEcCtD
Ramelteon—Myalgia—Mycophenolate mofetil—psoriasis	0.000634	0.00391	CcSEcCtD
Ramelteon—Arthralgia—Mycophenolate mofetil—psoriasis	0.000634	0.00391	CcSEcCtD
Ramelteon—Diarrhoea—Hydroxyurea—psoriasis	0.000629	0.00388	CcSEcCtD
Ramelteon—Dysgeusia—Triamcinolone—psoriasis	0.000625	0.00386	CcSEcCtD
Ramelteon—Anaphylactic shock—Cyclosporine—psoriasis	0.000623	0.00385	CcSEcCtD
Ramelteon—Dizziness—Hydroxyurea—psoriasis	0.000608	0.00375	CcSEcCtD
Ramelteon—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000608	0.00375	CcSEcCtD
Ramelteon—Myalgia—Hydrocortisone—psoriasis	0.000577	0.00357	CcSEcCtD
Ramelteon—Headache—Hydroxyurea—psoriasis	0.000576	0.00356	CcSEcCtD
Ramelteon—MTNR1A—GPCR downstream signaling—HCAR2—psoriasis	0.000568	0.0146	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR downstream signaling—HCAR2—psoriasis	0.000568	0.0146	CbGpPWpGaD
Ramelteon—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000567	0.0035	CcSEcCtD
Ramelteon—Anaphylactic shock—Prednisolone—psoriasis	0.000567	0.0035	CcSEcCtD
Ramelteon—Insomnia—Cyclosporine—psoriasis	0.000563	0.00348	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Methotrexate—psoriasis	0.000562	0.00347	CcSEcCtD
Ramelteon—Somnolence—Cyclosporine—psoriasis	0.000554	0.00342	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000553	0.00342	CcSEcCtD
Ramelteon—Anaphylactic shock—Hydrocortisone—psoriasis	0.000553	0.00342	CcSEcCtD
Ramelteon—Asthenia—Mycophenolic acid—psoriasis	0.000552	0.00341	CcSEcCtD
Ramelteon—Insomnia—Mycophenolate mofetil—psoriasis	0.000549	0.00339	CcSEcCtD
Ramelteon—Nausea—Hydroxyurea—psoriasis	0.000546	0.00337	CcSEcCtD
Ramelteon—Myalgia—Triamcinolone—psoriasis	0.000544	0.00336	CcSEcCtD
Ramelteon—Somnolence—Mycophenolate mofetil—psoriasis	0.00054	0.00334	CcSEcCtD
Ramelteon—Depression—Methotrexate—psoriasis	0.000538	0.00332	CcSEcCtD
Ramelteon—Fatigue—Cyclosporine—psoriasis	0.000537	0.00332	CcSEcCtD
Ramelteon—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000529	0.0136	CbGpPWpGaD
Ramelteon—Diarrhoea—Mycophenolic acid—psoriasis	0.000527	0.00325	CcSEcCtD
Ramelteon—MTNR1A—GPCR ligand binding—CCL20—psoriasis	0.000522	0.0134	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR ligand binding—CCL20—psoriasis	0.000522	0.0134	CbGpPWpGaD
Ramelteon—Anaphylactic shock—Triamcinolone—psoriasis	0.000521	0.00322	CcSEcCtD
Ramelteon—MTNR1A—Signaling by GPCR—HCAR2—psoriasis	0.000516	0.0133	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—HCAR2—psoriasis	0.000516	0.0133	CbGpPWpGaD
Ramelteon—Insomnia—Prednisolone—psoriasis	0.000513	0.00317	CcSEcCtD
Ramelteon—Dizziness—Mycophenolic acid—psoriasis	0.000509	0.00314	CcSEcCtD
Ramelteon—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000509	0.0131	CbGpPWpGaD
Ramelteon—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000504	0.00311	CcSEcCtD
Ramelteon—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000502	0.0129	CbGpPWpGaD
Ramelteon—Insomnia—Hydrocortisone—psoriasis	0.000501	0.00309	CcSEcCtD
Ramelteon—Myalgia—Dexamethasone—psoriasis	0.000493	0.00305	CcSEcCtD
Ramelteon—Myalgia—Betamethasone—psoriasis	0.000493	0.00305	CcSEcCtD
Ramelteon—Headache—Mycophenolic acid—psoriasis	0.000482	0.00298	CcSEcCtD
Ramelteon—Fatigue—Hydrocortisone—psoriasis	0.000477	0.00295	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000475	0.00293	CcSEcCtD
Ramelteon—Anaphylactic shock—Dexamethasone—psoriasis	0.000473	0.00292	CcSEcCtD
Ramelteon—Anaphylactic shock—Betamethasone—psoriasis	0.000473	0.00292	CcSEcCtD
Ramelteon—Insomnia—Triamcinolone—psoriasis	0.000471	0.00291	CcSEcCtD
Ramelteon—Nausea—Mycophenolic acid—psoriasis	0.000457	0.00282	CcSEcCtD
Ramelteon—Fatigue—Triamcinolone—psoriasis	0.000449	0.00278	CcSEcCtD
Ramelteon—Asthenia—Cyclosporine—psoriasis	0.000447	0.00276	CcSEcCtD
Ramelteon—Asthenia—Mycophenolate mofetil—psoriasis	0.000436	0.00269	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000431	0.00266	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000431	0.00266	CcSEcCtD
Ramelteon—Myalgia—Prednisone—psoriasis	0.00043	0.00265	CcSEcCtD
Ramelteon—Arthralgia—Prednisone—psoriasis	0.00043	0.00265	CcSEcCtD
Ramelteon—Insomnia—Betamethasone—psoriasis	0.000428	0.00264	CcSEcCtD
Ramelteon—Insomnia—Dexamethasone—psoriasis	0.000428	0.00264	CcSEcCtD
Ramelteon—Diarrhoea—Cyclosporine—psoriasis	0.000426	0.00263	CcSEcCtD
Ramelteon—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000416	0.00257	CcSEcCtD
Ramelteon—Dysgeusia—Methotrexate—psoriasis	0.000413	0.00255	CcSEcCtD
Ramelteon—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000412	0.0106	CbGpPWpGaD
Ramelteon—Dizziness—Cyclosporine—psoriasis	0.000412	0.00254	CcSEcCtD
Ramelteon—Anaphylactic shock—Prednisone—psoriasis	0.000412	0.00254	CcSEcCtD
Ramelteon—Fatigue—Dexamethasone—psoriasis	0.000408	0.00252	CcSEcCtD
Ramelteon—Fatigue—Betamethasone—psoriasis	0.000408	0.00252	CcSEcCtD
Ramelteon—Dizziness—Mycophenolate mofetil—psoriasis	0.000402	0.00248	CcSEcCtD
Ramelteon—MTNR1A—Circadian rythm related genes—LEP—psoriasis	0.000397	0.0102	CbGpPWpGaD
Ramelteon—MTNR1B—Circadian rythm related genes—LEP—psoriasis	0.000397	0.0102	CbGpPWpGaD
Ramelteon—Asthenia—Hydrocortisone—psoriasis	0.000397	0.00245	CcSEcCtD
Ramelteon—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000393	0.0101	CbGpPWpGaD
Ramelteon—Headache—Cyclosporine—psoriasis	0.00039	0.00241	CcSEcCtD
Ramelteon—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000387	0.00997	CbGpPWpGaD
Ramelteon—Headache—Mycophenolate mofetil—psoriasis	0.000381	0.00235	CcSEcCtD
Ramelteon—Diarrhoea—Hydrocortisone—psoriasis	0.000379	0.00234	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Prednisone—psoriasis	0.000375	0.00232	CcSEcCtD
Ramelteon—Dizziness—Prednisolone—psoriasis	0.000375	0.00231	CcSEcCtD
Ramelteon—Asthenia—Triamcinolone—psoriasis	0.000374	0.00231	CcSEcCtD
Ramelteon—Insomnia—Prednisone—psoriasis	0.000372	0.0023	CcSEcCtD
Ramelteon—MTNR1B—Circadian rythm related genes—NOS2—psoriasis	0.00037	0.00953	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—NOS2—psoriasis	0.00037	0.00953	CbGpPWpGaD
Ramelteon—Nausea—Cyclosporine—psoriasis	0.00037	0.00228	CcSEcCtD
Ramelteon—Dizziness—Hydrocortisone—psoriasis	0.000366	0.00226	CcSEcCtD
Ramelteon—Nausea—Mycophenolate mofetil—psoriasis	0.000361	0.00223	CcSEcCtD
Ramelteon—Myalgia—Methotrexate—psoriasis	0.000359	0.00222	CcSEcCtD
Ramelteon—Arthralgia—Methotrexate—psoriasis	0.000359	0.00222	CcSEcCtD
Ramelteon—Fatigue—Prednisone—psoriasis	0.000355	0.00219	CcSEcCtD
Ramelteon—Headache—Prednisolone—psoriasis	0.000355	0.00219	CcSEcCtD
Ramelteon—Headache—Hydrocortisone—psoriasis	0.000347	0.00214	CcSEcCtD
Ramelteon—MTNR1B—Circadian rythm related genes—PPARG—psoriasis	0.000346	0.00891	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—PPARG—psoriasis	0.000346	0.00891	CbGpPWpGaD
Ramelteon—Dizziness—Triamcinolone—psoriasis	0.000345	0.00213	CcSEcCtD
Ramelteon—Anaphylactic shock—Methotrexate—psoriasis	0.000344	0.00213	CcSEcCtD
Ramelteon—Asthenia—Dexamethasone—psoriasis	0.000339	0.0021	CcSEcCtD
Ramelteon—Asthenia—Betamethasone—psoriasis	0.000339	0.0021	CcSEcCtD
Ramelteon—Nausea—Prednisolone—psoriasis	0.000337	0.00208	CcSEcCtD
Ramelteon—Nausea—Hydrocortisone—psoriasis	0.000329	0.00203	CcSEcCtD
Ramelteon—Headache—Triamcinolone—psoriasis	0.000326	0.00202	CcSEcCtD
Ramelteon—Diarrhoea—Betamethasone—psoriasis	0.000324	0.002	CcSEcCtD
Ramelteon—Diarrhoea—Dexamethasone—psoriasis	0.000324	0.002	CcSEcCtD
Ramelteon—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000318	0.00819	CbGpPWpGaD
Ramelteon—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000314	0.00808	CbGpPWpGaD
Ramelteon—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000314	0.00194	CcSEcCtD
Ramelteon—Dizziness—Dexamethasone—psoriasis	0.000313	0.00193	CcSEcCtD
Ramelteon—Dizziness—Betamethasone—psoriasis	0.000313	0.00193	CcSEcCtD
Ramelteon—Insomnia—Methotrexate—psoriasis	0.000311	0.00192	CcSEcCtD
Ramelteon—Nausea—Triamcinolone—psoriasis	0.00031	0.00191	CcSEcCtD
Ramelteon—Somnolence—Methotrexate—psoriasis	0.000306	0.00189	CcSEcCtD
Ramelteon—MTNR1B—Signaling Pathways—HCAR2—psoriasis	0.000305	0.00785	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—HCAR2—psoriasis	0.000305	0.00785	CbGpPWpGaD
Ramelteon—Fatigue—Methotrexate—psoriasis	0.000297	0.00183	CcSEcCtD
Ramelteon—Headache—Betamethasone—psoriasis	0.000296	0.00183	CcSEcCtD
Ramelteon—Headache—Dexamethasone—psoriasis	0.000296	0.00183	CcSEcCtD
Ramelteon—Asthenia—Prednisone—psoriasis	0.000295	0.00183	CcSEcCtD
Ramelteon—MTNR1A—GPCR downstream signaling—CCL20—psoriasis	0.000295	0.0076	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR downstream signaling—CCL20—psoriasis	0.000295	0.0076	CbGpPWpGaD
Ramelteon—Diarrhoea—Prednisone—psoriasis	0.000282	0.00174	CcSEcCtD
Ramelteon—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000281	0.00723	CbGpPWpGaD
Ramelteon—Nausea—Betamethasone—psoriasis	0.000281	0.00173	CcSEcCtD
Ramelteon—Nausea—Dexamethasone—psoriasis	0.000281	0.00173	CcSEcCtD
Ramelteon—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000277	0.00713	CbGpPWpGaD
Ramelteon—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000273	0.00701	CbGpPWpGaD
Ramelteon—Dizziness—Prednisone—psoriasis	0.000272	0.00168	CcSEcCtD
Ramelteon—MTNR1B—Signaling by GPCR—CCL20—psoriasis	0.000268	0.0069	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—CCL20—psoriasis	0.000268	0.0069	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—TAGAP—psoriasis	0.000264	0.0068	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—TAGAP—psoriasis	0.000264	0.0068	CbGpPWpGaD
Ramelteon—Headache—Prednisone—psoriasis	0.000258	0.00159	CcSEcCtD
Ramelteon—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000249	0.00642	CbGpPWpGaD
Ramelteon—Asthenia—Methotrexate—psoriasis	0.000247	0.00153	CcSEcCtD
Ramelteon—MTNR1B—Circadian rythm related genes—JUN—psoriasis	0.000245	0.00632	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—JUN—psoriasis	0.000245	0.00632	CbGpPWpGaD
Ramelteon—Nausea—Prednisone—psoriasis	0.000245	0.00151	CcSEcCtD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000244	0.00628	CbGpPWpGaD
Ramelteon—Diarrhoea—Methotrexate—psoriasis	0.000235	0.00145	CcSEcCtD
Ramelteon—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000234	0.00601	CbGpPWpGaD
Ramelteon—MTNR1B—G alpha (i) signalling events—CXCL8—psoriasis	0.000233	0.006	CbGpPWpGaD
Ramelteon—MTNR1A—G alpha (i) signalling events—CXCL8—psoriasis	0.000233	0.006	CbGpPWpGaD
Ramelteon—Dizziness—Methotrexate—psoriasis	0.000228	0.00141	CcSEcCtD
Ramelteon—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000219	0.00564	CbGpPWpGaD
Ramelteon—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000216	0.00556	CbGpPWpGaD
Ramelteon—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000216	0.00555	CbGpPWpGaD
Ramelteon—Headache—Methotrexate—psoriasis	0.000216	0.00133	CcSEcCtD
Ramelteon—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000212	0.00547	CbGpPWpGaD
Ramelteon—Nausea—Methotrexate—psoriasis	0.000204	0.00126	CcSEcCtD
Ramelteon—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000189	0.00486	CbGpPWpGaD
Ramelteon—MTNR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000185	0.00477	CbGpPWpGaD
Ramelteon—MTNR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000185	0.00477	CbGpPWpGaD
Ramelteon—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00018	0.00464	CbGpPWpGaD
Ramelteon—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000169	0.00435	CbGpPWpGaD
Ramelteon—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000167	0.00429	CbGpPWpGaD
Ramelteon—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000163	0.00419	CbGpPWpGaD
Ramelteon—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000162	0.00417	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—TP53—psoriasis	0.000162	0.00417	CbGpPWpGaD
Ramelteon—MTNR1B—Circadian rythm related genes—TP53—psoriasis	0.000162	0.00417	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—CCL20—psoriasis	0.000158	0.00408	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—CCL20—psoriasis	0.000158	0.00408	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—IL6—psoriasis	0.000148	0.00382	CbGpPWpGaD
Ramelteon—MTNR1B—Circadian rythm related genes—IL6—psoriasis	0.000148	0.00382	CbGpPWpGaD
Ramelteon—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000146	0.00375	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR ligand binding—CXCL8—psoriasis	0.000141	0.00363	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR ligand binding—CXCL8—psoriasis	0.000141	0.00363	CbGpPWpGaD
Ramelteon—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000126	0.00325	CbGpPWpGaD
Ramelteon—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000126	0.00323	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000105	0.0027	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	9.07e-05	0.00233	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	8.73e-05	0.00225	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—SOCS1—psoriasis	8.72e-05	0.00224	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—SOCS1—psoriasis	8.72e-05	0.00224	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—TYK2—psoriasis	8.32e-05	0.00214	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—TYK2—psoriasis	8.32e-05	0.00214	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR downstream signaling—CXCL8—psoriasis	7.97e-05	0.00205	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR downstream signaling—CXCL8—psoriasis	7.97e-05	0.00205	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	7.92e-05	0.00204	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—CXCL8—psoriasis	7.24e-05	0.00186	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—CXCL8—psoriasis	7.24e-05	0.00186	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.79e-05	0.00175	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	6.79e-05	0.00175	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—LEP—psoriasis	6.44e-05	0.00166	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—APOE—psoriasis	6.44e-05	0.00166	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—LEP—psoriasis	6.44e-05	0.00166	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—APOE—psoriasis	6.44e-05	0.00166	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—NFKBIA—psoriasis	6e-05	0.00154	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—NFKBIA—psoriasis	6e-05	0.00154	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—NDUFA5—psoriasis	5.65e-05	0.00145	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.27e-05	0.00136	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—TYK2—psoriasis	4.91e-05	0.00126	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—TYK2—psoriasis	4.91e-05	0.00126	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—CYP2S1—psoriasis	4.81e-05	0.00124	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—NDUFA5—psoriasis	4.41e-05	0.00113	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—CXCL8—psoriasis	4.28e-05	0.0011	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—CXCL8—psoriasis	4.28e-05	0.0011	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.11e-05	0.00106	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—IL6—psoriasis	4.07e-05	0.00105	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—IL6—psoriasis	4.07e-05	0.00105	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—JUN—psoriasis	3.98e-05	0.00102	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—JUN—psoriasis	3.98e-05	0.00102	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—NFKB1—psoriasis	3.83e-05	0.000985	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—NFKB1—psoriasis	3.83e-05	0.000985	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—CYP2S1—psoriasis	3.75e-05	0.000964	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—VEGFA—psoriasis	3.47e-05	0.000894	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—VEGFA—psoriasis	3.47e-05	0.000894	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—STAT3—psoriasis	3.44e-05	0.000885	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—STAT3—psoriasis	3.44e-05	0.000885	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—NDUFA5—psoriasis	3.4e-05	0.000875	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—CYP2S1—psoriasis	2.89e-05	0.000744	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—TP53—psoriasis	2.62e-05	0.000675	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—TP53—psoriasis	2.62e-05	0.000675	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.52e-05	0.000648	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—IL6—psoriasis	2.4e-05	0.000618	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—IL6—psoriasis	2.4e-05	0.000618	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—CARM1—psoriasis	2.35e-05	0.000604	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.19e-05	0.000565	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.96e-05	0.000505	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—CARM1—psoriasis	1.83e-05	0.000471	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.71e-05	0.00044	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—CAT—psoriasis	1.44e-05	0.000372	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—CARM1—psoriasis	1.41e-05	0.000363	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—CAT—psoriasis	1.13e-05	0.00029	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—APOE—psoriasis	1.12e-05	0.000289	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—PPARG—psoriasis	9.77e-06	0.000252	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—APOE—psoriasis	8.74e-06	0.000225	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—CAT—psoriasis	8.68e-06	0.000223	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—PPARG—psoriasis	7.61e-06	0.000196	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—APOE—psoriasis	6.75e-06	0.000174	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—PPARG—psoriasis	5.88e-06	0.000151	CbGpPWpGaD
